PLX Options (PLX20260821C2.5) Price & Quote

Symbols

--(--)

Expected P&L on Expiry

Key Stats

0.00DAY`S RANGE0.00

Open

0.00

Prev.Close

0.00

Turnover

Volume

Premium

Extrinsic Value

Open Interest

Intrinsic Value

Pricing Model

Delta

Gamma

Theta

Vega

Rho

Theor Price

About PLX20260821C2.5

Underlying

Protalix Biotherapeutics, Inc.

Industry

Biological Technology

Introduction

Protalix Biotherapeutics, Inc., was originally incorporated in Florida in April 1992 and re-incorporated in Delaware in March 2016. The Company is a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by the proprietary ProCellEx plant cell protein expression system. The company is the first and only FDA-approved company to express suspension proteins through plant cells. The company's unique expression system represents a new way to develop recombinant proteins on an industrial scale. The company's strategic focus is to develop custom complex recombinant therapeutic proteins produced primarily through ProCellEx, while genetically engineering and chemically modifying proteins before and after production. The company intends to carry out such engineering and modification to provide additional clinical benefits by improving the biological properties of therapeutic proteins (e.g., glycosylation, half-life, immunogenicity).